

Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights

August 13, 2020

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Aug. 13, 2020-- Repare Therapeutics Inc. ("Repare") (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, as well as recent operational highlights.

"We set out in 2016 to become the leading precision oncology company focused on synthetic lethality in genomic instability and DNA damage repair, and have since built a strong pipeline of product candidates based upon our proprietary genome-wide, CRISPR enabled SNIPRx platform," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "With the successful completion of our initial public offering in June and our entry into a strategic collaboration with Bristol Myers Squibb in May, we have established a strong cash position to advance our pipeline. I am proud of our entire team and the remarkable progress they have made."

Operational Highlights:

- Initiated a phase 1/2 clinical trial evaluating RP-3500 as a monotherapy and in combination with Pfizer's PARPi, talazoparib. In July 2020, the Company received acceptance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application and commenced dosing for the first patient in the Phase 1/2 clinical trial of RP-3500.
- Completed initial public offering (IPO). In June 2020, Repare closed an upsized IPO of 12,650,000 of its common shares, including the exercise in full of the underwriters' option to purchase up to an additional 1,650,000 common shares, at a public offering price of \$20.00 per share. The net proceeds to Repare, after deducting underwriting commissions and offering expenses, were \$232 million.
- Bristol Myers Squibb collaboration. In May 2020, Repare entered into an exclusive, worldwide target discovery collaboration with Bristol Myers Squibb. Repare received an upfront payment from Bristol Myers Squibb of \$65 million in Q2 2020, which included a \$15 million equity investment in Repare in the form of a warrant that automatically exercised into 750,000 common shares at the public offering price of \$20.00 per share upon IPO. In addition, Repare will be eligible to receive additional contingent payments of up to approximately \$3 billion in the form of license fees, discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by Bristol Myers Squibb.
- Appointed new director. In June 2020, Repare appointed Ann D. Rhoads to its Board of Directors and as Chairperson of
 its Audit Committee.

Second Quarter 2020 Financial Results:

- Cash and restricted cash: Cash and restricted cash as of June 30, 2020 were \$370.1 million.
- Research and development expenses, net of tax credits (Net R&D): Net R&D expenses were \$9.0 million and \$17.6 million for the three and six month periods ended June 30, 2020, respectively, as compared to \$4.9 million and \$8.6 million in the same periods in the prior year, respectively. Increases in R&D for the three and six month periods ended June 30, 2020 were primarily due to increases in development costs related to Repare's RP-3500 and CCNE1-SL programs, as well as increases in personnel related expenses and certain other R&D expenses.
- General and administrative (G&A) expenses: G&A expenses were \$3.4 million and \$5.4 million for the three and six month periods ended June 30, 2020, respectively, as compared to \$1 million and \$2.1 million in the same periods in the prior year, respectively. Increases in G&A for the three and six month periods ended June 30, 2020 were due to increases in payroll and personnel costs as well as increases in legal, professional and D&O insurance costs, which in turn increased as a result of our recent IPO.
- Net loss: Net loss was \$11.8 million, or \$2.45 per share in the second quarter of 2020 and \$24.4 million, or \$7.56 per share, in the first half of 2020.

About Repare Therapeutics' SNIPRx® Platform

Repare's SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company's therapies based on the genetic profile of their tumors. Repare's platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those patients most likely to achieve clinical benefit from resulting product

candidates.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Pol® inhibitor programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company's collaboration with Bristol Myers Squibb; the discovery of potential product candidates using SNIPRx® platform; and the clinical development of the Company's pipeline and its research and development programs. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company's business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company's final prospectus dated June 18, 2020 and filed with the Securities and Exchange Commission pursuant to Rule 424(b) promulgated under the U.S. Securities Act of 1933, as amended. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Repare Therapeutics Inc. Condensed Consolidated Balance Sheets (Unaudited) (Amounts in thousands of U.S. dollars, except share data)

	As of June 30,			As of December 31,			
		2020	2019				
ASSETS							
CURRENT ASSETS:							
Cash	\$	369,933	\$	94,797			
Research and development tax credits receivable		1,414		1,080			
Other receivables		2,621		1,976			
Prepaid expenses and other current assets		3,296		719			
Total current assets		377,264		98,572			
Property and equipment, net		2,453		2,390			
Restricted cash		199		208			
Operating lease right-of-use assets		729		1,034			
Other assets		894		359			
Deferred tax assets		192		132			
TOTAL ASSETS	\$	381,731	\$	102,695			
LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)							
CURRENT LIABILITIES:							
Accounts payable	\$	3,576	\$	2,127			
Accrued expenses and other current liabilities		5,262		1,276			
Operating lease liability, current portion		608		625			
Income tax payable		351		218			
Total current liabilities		9,797		4,246			
Operating lease liability, net of current portion		136		439			
Deferred revenue		58,142		8,142			
TOTAL LIABILITIES		68,075		12,827			

Series A convertible preferred shares, no par value per share; 0 shares and unlimited shares authorized as of June 30, 2020 and December 31, 2019, respectively; 0 shares and 11,090,135 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively; liquidation and redemption value of \$0 and \$52,750 as of June 30, 2020 and December 31, 2019, respectively 53,749 Series B convertible preferred shares, no par value per share; 0 shares and unlimited shares authorized as of June 30, 2020 and December 31, 2019, respectively; 0 shares and 10,468,258 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively; liquidation and redemption value of \$0 and \$82,496 as of June 30, 2020 and December 31, 2019, 82,248 respectively **TOTAL CONVERTIBLE PREFERRED SHARES** 135,997 SHAREHOLDERS' EQUITY (DEFICIT) Preferred shares, no par value per share; unlimited shares and 0 shares authorized as of June 30, 2020 and December 31, 2019, respectively; 0 shares issued and outstanding as of June 30, 2020 and December 31, 2019 Common shares, no par value per share; unlimited shares authorized as of June 30, 2020 and December 31, 2019; 36,753,454 and 1,528,374 shares issued and outstanding as of June 30, 2020, and December 31, 2019, respectively 383,818 Additional paid-in capital 4,182 3,811 Accumulated deficit (49,941) (74,344)Total shareholders' equity (deficit) 313,656 (46, 129)TOTAL LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY 381,731 102,695 (DEFICIT)

Repare Therapeutics Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(Amounts in thousands of U.S. dollars, except share and per share data)

	Three Months Ended June 30,					Six Months Ended June 30,			
		2020	2019		2020			2019	
Operating expenses:									
Research and development, net of tax credits	\$	8,951	\$	4,853	\$	17,583	\$	8,556	
General and administrative		3,372		1,032		5,555		2,108	
Total operating expenses		12,323		5,885		23,138		10,664	
Loss from operations		(12,323)		(5,885)		(23,138)		(10,664)	
Other income (expense), net									
Realized and unrealized gain (loss) on foreign exchange		595		227		(1,136)		299	
Change in fair value of Series A preferred share tranche obligation		_		(680)		_		(700)	
Other expense		(4)		(1)		(6)		(3)	
Total other income (expense), net		591		(454)		(1,142)		(404)	
Loss before income taxes		(11,732)		(6,339)		(24,280)		(11,068)	
Income tax expense		(70)		(20)		(123)		(129)	
Net loss and comprehensive loss	\$	(11,802)	\$	(6,359)	\$	(24,403)	\$	(11,197)	
Net loss attributable to common shareholders—basic and diluted	\$	(11,802)	\$	(6,359)	\$	(24,403)	\$	(11,197)	
Net loss per share attributable to common shareholders—basic and diluted	\$	(2.45)	\$	(4.16)	\$	(7.56)	\$	(7.33)	
Weighted-average common shares outstanding—basic and diluted		4,825,214		1,528,374		3,229,635		1,528,374	

Repare Therapeutics Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (Amounts in thousands of U.S. dollars)

Six	Months	Ended
	luna 2	^

		June 30,					
	2020			2019			
Cash Flows From Operating Activities:							
Net loss and comprehensive loss for the period	\$	(24,403)	\$	(11,197)			
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:							

Depreciation expense 403 262 Change in fair value of the Series A preferred shares tranche obligation 305 80 Non-cash lease expense 305 80 Foreign exchange loss (gain) 1,162 (522) Changes in operating assets and diabilities:	Share-based compensation expense		660	186
Non-cash lease expense 305 86 Foreign excharage loss gain) 1,162 (522) Changes in operating assets and liabilities:	Depreciation expense		403	262
Foreign exchange loss (gain) 1,162 (522) Changes in operating assets and liabilities: 7 (155) Prepaid expenses and other current assets (2,577) (155) Research and development tax credits receivable (381) (246) Other receivables (60) (42) Other non-current assets (60) (42) Accounts payable 915 260 Accounts payable 133 72 Operating lease liability, current portion (9) 15 Income tax payable 133 72 Operating lease liability, not of current portion 26,937 (3,232) Operating lease liability, our ent portion 50,000 8,142 Net cash provided by (used in) operating activities 26,957 (3,232) Cash Flows From Investing Activities: 26,957 (3,232) Purchase of property and equipment 43 (380) Net cash used in investing activities 26,957 20,956 Cash Flows From Financing Activities: 20 20 Proceeds from issuance of Series A preferred shares, n	Change in fair value of the Series A preferred shares tranche obligation		_	700
Changes in operating assets and liabilities: (2,577) (155) Prepaid expenses and other current assets (381) (246) Other receivables (762) (566) Deferred tax asset (60) (42) Other non-current assets (535) (15) Accounts payable 915 200 Accrued expenses and other current liabilities 2,371 (119) Operating lease liability, current portion (93) 15 Income tax payable 133 72 Operating lease liability, net of current portion (93) (333) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 (3,232) Porteating lease liability, net of current portion (43) (380) Net cash provided by (used in) operating activities 26,967 (3,232) Potered revenue (43) (380) Net cash provided by (used in) operating activities 26,967 (3,232) Proceeds from issuance of Series A preferred shares, net 2 20,995 Proceeds from iss	Non-cash lease expense		305	86
Prepaid expenses and other current assets (2,577) (155) Research and development tax credits receivable (311) (246) Other receivables (725) (566) Deferred tax asset (606) (422) Other non-current assets (535) (150) Accounds payable 915 200 Accound expenses and other current liabilities 915 200 Accound please liability, current portion (98) 153 72 Operating lease liability, net of current portion (90) 133 72 Operating lease liability, net of current portion (200) 8,142 Operating lease liability, net of current portion (200) 8,142 Net cash provided by (used in) operating activities 26,967 (3,232) Poperating lease liability, net of current portion (43) (380) Net cash provided by (used in) operating activities 26,967 (3,232) Purchase of property and equipment (43) (380) Proceads from insuance of Series A preferred shares, net — — 20,955 Proceads	Foreign exchange loss (gain)		1,162	(522)
Research and development tax credits receivable (381) (248) Other receivables (75) (566) Deferred tax asset (60) (42) Other non-current assets (535) (15) Accounts payable 915 260 Accrued expenses and other current liabilities 2,371 (119) Operating lease liability, current portion (9) 15 Income tax payable 313 72 Operating lease liability, eut of current portion (292) (83) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,607 3,232 Purchase of property and equipment (43) 380 Net cash used in investing activities 2 20,955 Proceeds from investing activities 48 4 Proceeds from issuance of Series A preferred shares, net 48 4 Proceeds from issuance of Series A preferred shares, in initial public offering 233,760 4 Net cash provided by financing activities 275,127 17,865 Cash and restricted cas	Changes in operating assets and liabilities:			
Other receivables (725) (566) Deferred tax asset (60) (42) Other non-current assets (535) (15) Accounts payable 915 260 Accrued expenses and other current liabilities 2,371 (119) Operating lease liability, current portion (9) 15 Income tax payable 133 72 Operating lease liability, net of current portion (292) (93) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 (3,232) Cash Flows From Investing Activities (43) (380) Cash Flows From Investing activities (43) (380) Cash Flows From Financing Activities (43) (380) Cash Flows From Financing Activities (43) (380) Proceeds from issuance of Series A preferred shares, net (43) (48) (49) Proceeds from issuance of series A preferred shares, net (48) (49) (49) Proceeds from issuance of series A preferred shares, net (5) (49) (49	Prepaid expenses and other current assets		(2,577)	(155)
Deferred tax asset (60) (42) Other non-current assets (535) (15) Accounds payable 915 260 Accrued expenses and other current liabilities 2,371 (119) Operating lease liability, current portion (9) 15 Income tax payable 133 72 Operating lease liability, net of current portion (292) (93) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 (3,232) Experimental patrivities Purchase of property and equipment (43) (380) Net cash used in investing activities (43) (380) Proceeds from issuance of Series A preferred shares, net — 20,995 Proceeds from issuance of Series A preferred shares, net 48 — Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of warrant 15,000 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held 1,045	Research and development tax credits receivable		(381)	(246)
Other non-current assets (535) (15) Accounts payable 915 260 Accounts payable 2,371 (119) Operating lease liability, current portion (9) 15 Income tax payable 133 72 Operating lease liability, net of current portion (292) (93) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 (3,232) Cash Flows From Investing Activities (43) (380) Purchase of property and equipment (43) (380) Net cash used in investing activities (43) (380) Proceeds from issuance of Series A preferred shares, net — 20,995 Proceeds from issuance of Series A preferred shares, net 15,000 — Proceeds from issuance of Varrant 15,000 — Net cash provided by financing activities 233,60 — Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of warrant 15,000 — Net proceeds from issuance of series A preferred s	Other receivables		(725)	(566)
Accounts payable 915 260 Accrued expenses and other current liabilities 2,371 (119) Operating lease liability, current portion (9) 15 Income tax payable 133 72 Operating lease liability, net of current portion 50,000 8,142 Net cash provided by (used in) operating activities 26,967 (3,232) Test Flows From Investing Activities 4(3) (380) Purchase of property and equipment (43) (380) Net cash used in investing activities 4(43) (380) Proceeds from insuance of Series A preferred shares, net 5 20,995 Proceeds from issuance of Series A preferred shares, net 15,000 Proceeds from issuance of Varrant 15,000 Net proceeds from issuance of owarrant 15,000 Net proceeds from issuance of owarrant 249,248 20,995 Effect of exchange rate fluctuations on cash held 1,045 482 Net proceeds from issuance of owarrant 35,001 95,005 Effect of exchange rate fluctuations on cash held 36,053 <td>Deferred tax asset</td> <td></td> <td>(60)</td> <td>(42)</td>	Deferred tax asset		(60)	(42)
Accrued expenses and other current liabilities 2,371 (119) Operating lease liability, current portion (9) 15 Income tax payable 133 72 Operating lease liability, net of current portion (292) (93) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 (3,232) Cash Flows From Investing Activities: Purchase of property and equipment (43) (380) Net cash used in investing activities (43) (380) Cash Flows From Investing Activities: Proceeds from issuance of Series A preferred shares, net 9 20,995 Proceeds from exercise of stock options 488 - Proceeds from issuance of warrant 15,000 - Net proceeds from issuance of common shares in initial public offering 233,760 - Proceeds from issuance of warrant 10,000 - Net proceeds from issuance of warrant 10,000 - Net proceeds from issuance of warrant 10,000 - Net proceeds from issuance o	Other non-current assets		(535)	(15)
Operating lease liability, current portion (9) 15 Income tax payable 133 72 Operating lease liability, net of current portion (93) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 3,2329 Cash Flows From Investing Activities:	Accounts payable		915	260
Income tax payable 133 72 Operating lease liability, net of current portion (292) (93) Defered revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 3,232 East Flows From Investing Activities (43) 380 Purchase of property and equipment (43) 380 Net cash used in investing activities (43) 380 Proceeds from issuance of Series A preferred shares, net 9 20,995 Proceeds from issuance of Series A preferred shares, net 15,000 - Proceeds from issuance of variant 15,000 - Proceeds from issuance of warrant 15,000 - Net proceeds from issuance of common shares in initial public offering 23,760 - Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held 1,045 48 As and restricted cash at Deginning of period 95,005 10,929 Cash and restricted cash at end of period 95,005 28,794 Cash 369,933 28,588 </td <td>Accrued expenses and other current liabilities</td> <td></td> <td>2,371</td> <td>(119)</td>	Accrued expenses and other current liabilities		2,371	(119)
Operating lease liability, net of current portion (292) (39) Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 (3,23) Cash Flows From Investing Activities: Purchase of property and equipment (43) (380) Net cash used in investing activities (43) (380) Cash Flows From Investing activities Proceeds from issuance of Series A preferred shares, net — 20,995 Proceeds from issuance of Series A preferred shares, net — 20,995 Proceeds from issuance of varrant 15,000 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net proceeds from issuance of common shares in initial public offering 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net proceeds from issuance of common shares in initial public offering 275,127 17,865 Cash and restricted cash at Beginning of period 95,005 10,929 As and restricted cash at end of period 95,005 10,929 Ca	Operating lease liability, current portion		(9)	15
Deferred revenue 50,000 8,142 Net cash provided by (used in) operating activities 26,967 3,232 Cash Flows From Investing Activities: 4(3) (380) Purchase of property and equipment (43) (380) Net cash used in investing activities 4(3) (380) Cash Flows From Financing Activities: 2 20,995 Proceeds from issuance of Series A preferred shares, net 5 20,995 Proceeds from issuance of varrant 15,000 - Proceeds from issuance of varrant 15,000 - Net proceeds from issuance of varrant 15,000 - Net proceeds from issuance of common shares in initial public offering 233,760 - Proceeds from issuance of varrant (1,045) 482 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at end of period 369,033 28,789 Rescricted cash 369,033 28,789 Restricted cash 369,033 28,789 <	Income tax payable		133	72
Net cash provided by (used in) operating activities 26,967 (3,232) Cash Flows From Investing Activities: (43) (380) Purchase of property and equipment (43) (380) Net cash used in investing activities (43) (380) Cash Flows From Financing Activities: To cash Investing activities 20,995 Proceeds from issuance of Series A preferred shares, net 15,000 Proceeds from exercise of stock options 488 Proceeds from issuance of warrant 15,000 Net proceeds from issuance of common shares in initial public offering 233,760 Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$ 369,933 28,588 Cash \$ 369,933 28,588 Restricted cash 199 206 Total cash and restricted cash	Operating lease liability, net of current portion		(292)	(93)
Cash Flows From Investing Activities: Purchase of property and equipment (43) (380) Net cash used in investing activities (43) (380) Cash Flows From Financing Activities: Proceeds from issuance of Series A preferred shares, net — 20,995 Proceeds from issuance of Series A preferred shares, net — 20,995 Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net proceeds from issuance of scommon shares in initial public offering 233,760 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$ 369,933 28,788 Restricted cash \$ 369,933 28,788 Restricted cash \$ 369,933 28,788 Restricted cash \$ 369,933 28,7	Deferred revenue		50,000	8,142
Purchase of property and equipment Net cash used in investing activities (43) (380) Cash Flows From Financing Activities: Secondary Investing Activities Activate Activa	Net cash provided by (used in) operating activities		26,967	(3,232)
Net cash used in investing activities (43) (380) Cash Flows From Financing Activities: Proceeds from issuance of Series A preferred shares, net 20,995 Proceeds from exercise of stock options 488 — Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period 370,132 28,794 Reconciliation Of Cash And Restricted Cash Cash \$369,933 28,588 Restricted cash 199 206 Total cash and restricted cash 370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$423 14 Initial public offering costs in accounts payable \$1,615	Cash Flows From Investing Activities:			
Cash Flows From Financing Activities: Proceeds from issuance of Series A preferred shares, net 20,995 Proceeds from exercise of stock options 488 — Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$370,132 28,794 Reconciliation Of Cash And Restricted Cash Cash \$369,933 \$28,588 Restricted cash 199 206 Total cash and restricted cash \$370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$423 14 Initial public offeri	Purchase of property and equipment		(43)	 (380)
Proceeds from issuance of Series A preferred shares, net — 20,995 Proceeds from exercise of stock options 488 — Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase in Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$370,132 28,794 Reconciliation Of Cash And Restricted Cash Cash \$369,933 28,588 Restricted cash 199 206 Total cash and restricted cash 370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable 423 14 Initial public offering costs in accounts payable 102 — Initial public offering costs in accounts payable 1,615 —	Net cash used in investing activities		(43)	 (380)
Proceeds from exercise of stock options 488 — Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$ 370,132 \$ 28,794 Reconciliation Of Cash And Restricted Cash Cash \$ 369,933 \$ 28,588 Restricted cash 199 206 Total cash and restricted cash \$ 370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$ 423 \$ 14 Initial public offering costs in accounts payable \$ 1,615 — Initial public offering costs in accruals and other current liabilities \$ 1,615 — Conversion of Series A and B convertible preferred shares into common shares	Cash Flows From Financing Activities:			 <u> </u>
Proceeds from issuance of warrant 15,000 — Net proceeds from issuance of common shares in initial public offering 233,760 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase in Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$ 370,132 28,794 Reconciliation Of Cash And Restricted Cash Cash \$ 369,933 28,588 Restricted cash 199 206 Total cash and restricted cash \$ 370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$ 423 14 Initial public offering costs in accounts payable \$ 1,615 — Initial public offering costs in accruals and other current liabilities \$ 1,615 — Conversion of Series A and B convertible preferred shares into common shares 135,997 —	Proceeds from issuance of Series A preferred shares, net		_	20,995
Net proceeds from issuance of common shares in initial public offering 233,760 — Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$370,132 28,794 Reconciliation Of Cash And Restricted Cash Cash \$369,933 \$28,588 Restricted cash 199 206 Total cash and restricted cash \$370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$423 14 Initial public offering costs in accounts payable \$102 102 Initial public offering costs in accruals and other current liabilities \$1,615 — Conversion of Series A and B convertible preferred shares into common shares \$135,997 —	Proceeds from exercise of stock options		488	_
Net cash provided by financing activities 249,248 20,995 Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$370,132 28,794 Reconciliation Of Cash And Restricted Cash Cash \$369,933 28,588 Restricted cash 199 206 Total cash and restricted cash \$370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$423 14 Initial public offering costs in accounts payable \$102 1 Initial public offering costs in accruals and other current liabilities \$1,615 — Conversion of Series A and B convertible preferred shares into common shares \$135,997 —	Proceeds from issuance of warrant		15,000	_
Effect of exchange rate fluctuations on cash held (1,045) 482 Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$ 370,132 28,794 Reconciliation Of Cash And Restricted Cash \$ 369,933 \$ 28,588 Restricted cash 199 206 Total cash and restricted cash \$ 370,132 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$ 423 \$ 14 Initial public offering costs in accounts payable \$ 102 \$ 102 Initial public offering costs in accruals and other current liabilities \$ 1,615 \$ — Conversion of Series A and B convertible preferred shares into common shares \$ 135,997 \$ —	Net proceeds from issuance of common shares in initial public offering		233,760	
Net Increase In Cash And Restricted Cash 275,127 17,865 Cash and restricted cash at beginning of period 95,005 10,929 Cash and restricted cash at end of period \$ 370,132 \$ 28,794 Reconciliation Of Cash And Restricted Cash Cash \$ 369,933 \$ 28,588 Restricted cash 199 206 Total cash and restricted cash \$ 370,132 \$ 28,794 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$ 423 \$ 14 Initial public offering costs in accounts payable \$ 102 — Initial public offering costs in accruals and other current liabilities \$ 1,615 — Conversion of Series A and B convertible preferred shares into common shares \$ 135,997 \$ —	Net cash provided by financing activities		249,248	20,995
Cash and restricted cash at beginning of period Cash and restricted cash at end of period Reconciliation Of Cash And Restricted Cash Cash Restricted cash Restricted cash Total cash and restricted cash Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable Initial public offering costs in accounts payable Initial public offering costs in accruals and other current liabilities Conversion of Series A and B convertible preferred shares into common shares 10,929 28,794 28,588 28,588 28,588 28,794 28,794 28,794 28,794 28,794	Effect of exchange rate fluctuations on cash held		(1,045)	482
Cash and restricted cash at end of period\$ 370,132\$ 28,794Reconciliation Of Cash And Restricted CashCash\$ 369,933\$ 28,588Restricted cash199206Total cash and restricted cash\$ 370,132\$ 28,794Supplemental Disclosure Of Cash Flow Information:Property and equipment purchases in accounts payable\$ 423\$ 14Initial public offering costs in accounts payable\$ 102Initial public offering costs in accruals and other current liabilities\$ 1,615\$ —Conversion of Series A and B convertible preferred shares into common shares\$ 135,997\$ —	Net Increase In Cash And Restricted Cash		275,127	17,865
Reconciliation Of Cash And Restricted Cash Cash Restricted cash Total cash and restricted cash Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable Initial public offering costs in accounts payable Initial public offering costs in accruals and other current liabilities Conversion of Series A and B convertible preferred shares into common shares **Total cash And Restricted Cash** \$ 369,933 \$ 28,588 **Total cash and restricted cash **Total cash and restricted	Cash and restricted cash at beginning of period		95,005	 10,929
Cash Restricted cash 199 206 Total cash and restricted cash \$370,132 \$28,588 Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable \$423 \$14 Initial public offering costs in accounts payable \$102 Initial public offering costs in accruals and other current liabilities \$1,615 \$— Conversion of Series A and B convertible preferred shares into common shares \$135,997 \$—	Cash and restricted cash at end of period	\$	370,132	\$ 28,794
Restricted cash Total cash and restricted cash Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable Initial public offering costs in accounts payable Initial public offering costs in accruals and other current liabilities Conversion of Series A and B convertible preferred shares into common shares 199 206 28,794 1423 5 14 15 1615 5 - Conversion of Series A and B convertible preferred shares into common shares	Reconciliation Of Cash And Restricted Cash			
Total cash and restricted cash Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable Initial public offering costs in accounts payable Initial public offering costs in accruals and other current liabilities Conversion of Series A and B convertible preferred shares into common shares \$ 370,132 \$ 28,794 \$ 14 14 10 10 10 10 10 10 10	Cash	\$	369,933	\$ 28,588
Supplemental Disclosure Of Cash Flow Information: Property and equipment purchases in accounts payable Initial public offering costs in accounts payable Initial public offering costs in accruals and other current liabilities Conversion of Series A and B convertible preferred shares into common shares Supplemental Disclosure Of Cash Flow Information: \$ 1423	Restricted cash		199	206
Property and equipment purchases in accounts payable Initial public offering costs in accounts payable Initial public offering costs in accruals and other current liabilities Solvential public offering costs in accruals and other current liabilities Conversion of Series A and B convertible preferred shares into common shares \$ 135,997	Total cash and restricted cash	\$	370,132	\$ 28,794
Initial public offering costs in accounts payable Initial public offering costs in accruals and other current liabilities \$ 1,615 \$ — Conversion of Series A and B convertible preferred shares into common shares \$ 135,997 \$ —	Supplemental Disclosure Of Cash Flow Information:			
Initial public offering costs in accruals and other current liabilities \$ 1,615 \$ — Conversion of Series A and B convertible preferred shares into common shares \$ 135,997 \$ —	Property and equipment purchases in accounts payable	\$	423	\$ 14
Initial public offering costs in accruals and other current liabilities \$ 1,615 \$ — Conversion of Series A and B convertible preferred shares into common shares \$ 135,997 \$ —	Initial public offering costs in accounts payable	\$	102	
Conversion of Series A and B convertible preferred shares into common shares \$ 135,997 \$ —	· · · · · · · · · · · · · · · · · · ·	\$	1,615	\$ _
	•	<u> </u>		
	·	<u></u>		 _

View source version on <u>businesswire.com</u>: <u>https://www.businesswire.com/news/home/20200813005641/en/</u>

Repare Contact:

Steve Forte Chief Financial Officer Repare Therapeutics Inc. info@reparerx.com

Investors:

Kimberly Minarovich Argot Partners repare@argotpartners.com

Media:

David Rosen Argot Partners david.rosen@argotpartners.com 212-600-1902

Source: Repare Therapeutics Inc.